Trump touted a big initiative to treat kidney disease more effectively, an initiative that will go away if Trump prevails in his lawsuit to overturn the Affordable Care Act. Oh, well.
Then his big push to make prescription drugs cheaper, an issue that rivals infrastructure in the frequency with which Trump makes big promises, fell through. Unlike infrastructure, his plan to lower drug prices actually got as far as a proposed rule, but it was yanked back last week. The idea behind it was to ban drug rebates that the drug companies give to insurance middlemen for negotiating prices in government programs like Medicare. The belief was that the rebates were inflating drug prices for the benefit of those rebate brokers, and by getting rid of them the savings would be passed on to consumers.